Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Efficacy of hydroxychloroquine in pre-exposure severe acute respiratory syndrome coronavirus 2 prophylaxis among high-risk healthcare workers: A multicenter study

Nasri et al., Advanced Biomedical Research, doi:10.4103/abr.abr_104_21, IRCT20200414047076N1
Jan 2023  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Symp. case, severe 92% Improvement Relative Risk Symp. case, moderate/se.. 85% Symp. case, all 48% HCQ  Nasri et al.  Prophylaxis  RCT Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? RCT 143 patients in Iran (August - November 2020) Fewer symptomatic cases with HCQ (p=0.028) c19hcq.org Nasri et al., Advanced Biomedical Rese.., Jan 2023 FavorsHCQ Favorscontrol 0 0.5 1 1.5 2+
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now with p < 0.00000000001 from 411 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments. c19hcq.org
RCT 143 healthcare workers in Iran, showing lower cases with HCQ prophylaxis, statistically significant only for moderate/severe cases. Baseline details are not provided.
risk of symptomatic case, 92.2% lower, RR 0.08, p = 0.03, treatment 0 of 70 (0.0%), control 6 of 73 (8.2%), NNT 12, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), severe cases.
risk of symptomatic case, 85.1% lower, RR 0.15, p = 0.003, treatment 2 of 70 (2.9%), control 14 of 73 (19.2%), NNT 6.1, moderate or severe cases.
risk of symptomatic case, 47.9% lower, RR 0.52, p = 0.16, treatment 7 of 70 (10.0%), control 14 of 73 (19.2%), NNT 11, all cases.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Nasri et al., 27 Jan 2023, Randomized Controlled Trial, Iran, peer-reviewed, mean age 29.7, 11 authors, study period 11 August, 2020 - 11 November, 2020, trial IRCT20200414047076N1.
This PaperHCQAll
Efficacy of hydroxychloroquine in pre-exposure severe acute respiratory syndrome coronavirus 2 prophylaxis among high-risk healthcare workers: A multicenter study
Dr Afsane Vaezi, Elahe Nasri, Hamed Fakhim, Mehrdad Salahi, Safiyeh Ghafel, Samane Pourajam, Ali Darakhshandeh, Nazila Kassaian, Somayeh Sadeghi, Behrooz Ataei, Shaghayeghhaghjooy Javanmard
Advanced Biomedical Research, doi:10.4103/abr.abr_104_21
The novel coronavirus disease 2019 (COVID-19) is a highly contagious infection associated with significant mortality and morbidity among risk groups and a devastating local economic burden around the world. [1, 2] During the pandemic,
Ethical conduct of research Conflicts of interest There are no conflicts of interest.
References
Abella, Jolkovsky, Biney, Uspal, Hyman et al., Efficacy and safety of hydroxychloroquine vs. placebo for preexposure SARS-CoV-2 prophylaxis among health care workers: A randomized clinical trial, JAMA Intern Med
Boulware, Pullen, Bangdiwala, Pastick, Lofgren et al., A randomized trial of hydroxychloroquine as postexposure prophylaxis for covid-19, N Engl J Med
Chang, Park, Kim, Park, Risk factors for disease progression in COVID-19 patients, BMC Infect Dis
Chang, Sun, Repositioning chloroquine as ideal antiviral prophylactic against COVID-19-time is now, Drug Discov Today
Cheng, Group, A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19), PLoS One
Fegert, Vitiello, Plener, Clemens, Challenges and burden of the coronavirus 2019 (COVID-19) pandemic for child and adolescent mental health: A narrative review to highlight clinical and research needs in the acute phase and the long return to normality, Child Adolesc Psychiatry Ment Health
Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial, Int J Antimicrob Agents
Guitti, Parnaz, Parichehr, Fariba, Prophylactic recommendation for healthcare workers in COVID-19 pandemic, Adv J Emerg Med
Hu, Song, Xu, Chen, Xu, Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China, Sci China Life Sci
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Joutei Hassani, Bennis, Hydroxychloroquine as antiviral prophylaxis for exposed caregivers to Covid-19: An urgent appraisal is needed, J Infect Public Health
Keshavan, Hospital Workers Across the U.S. Present Sharply Different Pictures of their Preparedness for the Coronavirus
Lee, Son, Peck, Can post-exposure prophylaxis for COVID-19 be considered as one of outbreak response strategies in long-term care hospitals?, Int J Antimicrob Agents
Liu, Cao, Xu, Wang, Zhang et al., Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov
Marmor, Carr, Easterbrook, Farjo, Mieler et al., Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: A report by the American Academy of Ophthalmology, Ophthalmology
Mohammadi, Pourzamani, Karimi, Mohammadi, Mohammadi et al., Artificial neural network and logistic regression modelling to characterize COVID-19 infected patients in local areas of Iran, Biomed J
Parhizgar, Tahghighi, Introducing new antimalarial analogues of chloroquine and amodiaquine: A narrative review, Iran J Med Sci
Pereira, Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: A timely review, J Toxicol Environ Health B Crit Rev
Rajasingham, Bangdiwala, Nicol, Skipper, Pastick et al., Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: A randomized trial, medRxiv
Rosenberg, Dufort, Udo, Wilberschied, Kumar et al., Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State, JAMA
Sahu, Amrithanand, Mathew, Aggarwal, Nayer et al., COVID-19 in health care workers -A systematic review and metaanalysis, Am J Emerg Med
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res
Winzeler, Malaria research in the post-genomic era, Nature
{ 'indexed': { 'date-parts': [[2023, 10, 28]], 'date-time': '2023-10-28T11:45:34Z', 'timestamp': 1698493534025}, 'reference-count': 25, 'publisher': 'Medknow', 'issue': '1', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2023]]}, 'DOI': '10.4103/abr.abr_104_21', 'type': 'journal-article', 'created': {'date-parts': [[2023, 2, 2]], 'date-time': '2023-02-02T08:58:19Z', 'timestamp': 1675328299000}, 'page': '3', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Efficacy of hydroxychloroquine in pre-exposure severe acute respiratory syndrome coronavirus 2 ' 'prophylaxis among high-risk healthcare workers: A multicenter study', 'prefix': '10.4103', 'volume': '12', 'author': [ {'given': 'Afsane', 'family': 'Vaezi', 'sequence': 'first', 'affiliation': []}, {'given': 'Elahe', 'family': 'Nasri', 'sequence': 'additional', 'affiliation': []}, {'given': 'Hamed', 'family': 'Fakhim', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mehrdad', 'family': 'Salahi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Safiyeh', 'family': 'Ghafel', 'sequence': 'additional', 'affiliation': []}, {'given': 'Samane', 'family': 'Pourajam', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ali', 'family': 'Darakhshandeh', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nazila', 'family': 'Kassaian', 'sequence': 'additional', 'affiliation': []}, {'given': 'Somayeh', 'family': 'Sadeghi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Behrooz', 'family': 'Ataei', 'sequence': 'additional', 'affiliation': []}, { 'given': 'ShaghayeghHaghjooy', 'family': 'Javanmard', 'sequence': 'additional', 'affiliation': []}], 'member': '2581', 'reference': [ { 'key': 'key-10.4103/2277-9175.368527-1', 'doi-asserted-by': 'crossref', 'first-page': '445', 'DOI': '10.1186/s12879-020-05144-x', 'article-title': 'Risk factors for disease progression in COVID-19 patients', 'author': 'Chang', 'year': '2020', 'journal-title': 'BMC Infect Dis'}, { 'key': 'key-10.4103/2277-9175.368527-2', 'doi-asserted-by': 'crossref', 'first-page': '20', 'DOI': '10.1186/s13034-020-00329-3', 'article-title': 'Challenges and burden of the coronavirus 2019 (COVID-19) pandemic for ' 'child and adolescent mental health: A narrative review to highlight ' 'clinical and research needs in the acute phase and the long return to ' 'normality', 'author': 'Fegert', 'year': '2020', 'journal-title': 'Child Adolesc Psychiatry Ment Health'}, { 'key': 'key-10.4103/2277-9175.368527-3', 'doi-asserted-by': 'crossref', 'first-page': '706', 'DOI': '10.1007/s11427-020-1661-4', 'article-title': 'Clinical characteristics of 24 asymptomatic infections with COVID-19 ' 'screened among close contacts in Nanjing, China', 'author': 'Hu', 'year': '2020', 'journal-title': 'Sci China Life Sci'}, { 'key': 'key-10.4103/2277-9175.368527-4', 'doi-asserted-by': 'crossref', 'first-page': '1727', 'DOI': '10.1016/j.ajem.2020.05.113', 'article-title': 'COVID-19 in health care workers – A systematic review and meta-analysis', 'author': 'Sahu', 'year': '2020', 'journal-title': 'Am J Emerg Med'}, { 'key': 'key-10.4103/2277-9175.368527-5', 'doi-asserted-by': 'crossref', 'first-page': '751', 'DOI': '10.1038/nature07361', 'article-title': 'Malaria research in the post-genomic era', 'author': 'Winzeler', 'year': '2008', 'journal-title': 'Nature'}, { 'key': 'key-10.4103/2277-9175.368527-6', 'first-page': '115', 'article-title': 'Introducing new antimalarial analogues of chloroquine and amodiaquine: ' 'A narrative review', 'author': 'Parhizgar', 'year': '2017', 'journal-title': 'Iran J Med Sci'}, { 'key': 'key-10.4103/2277-9175.368527-7', 'doi-asserted-by': 'crossref', 'first-page': '16', 'DOI': '10.1038/s41421-020-0156-0', 'article-title': 'Hydroxychloroquine, a less toxic derivative of chloroquine, is ' 'effective in inhibiting SARS-CoV-2 infection in vitro', 'author': 'Liu', 'year': '2020', 'journal-title': 'Cell Discov'}, { 'key': 'key-10.4103/2277-9175.368527-8', 'doi-asserted-by': 'crossref', 'first-page': '269', 'DOI': '10.1038/s41422-020-0282-0', 'article-title': 'Remdesivir and chloroquine effectively inhibit the recently emerged ' 'novel coronavirus (2019-nCoV) in vitro', 'author': 'Wang', 'year': '2020', 'journal-title': 'Cell Res'}, { 'key': 'key-10.4103/2277-9175.368527-9', 'doi-asserted-by': 'crossref', 'first-page': '105949', 'DOI': '10.1016/j.ijantimicag.2020.105949', 'article-title': 'Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results ' 'of an open-label non-randomized clinical trial', 'author': 'Gautret', 'year': '2020', 'journal-title': 'Int J Antimicrob Agents'}, { 'key': 'key-10.4103/2277-9175.368527-10', 'doi-asserted-by': 'crossref', 'first-page': '105988', 'DOI': '10.1016/j.ijantimicag.2020.105988', 'article-title': 'Can post-exposure prophylaxis for COVID-19 be considered as one of ' 'outbreak response strategies in long-term care hospitals?', 'author': 'Lee', 'year': '2020', 'journal-title': 'Int J Antimicrob Agents'}, { 'key': 'key-10.4103/2277-9175.368527-11', 'doi-asserted-by': 'crossref', 'first-page': '517', 'DOI': '10.1056/NEJMoa2016638', 'article-title': 'A randomized trial of hydroxychloroquine as postexposure prophylaxis ' 'for covid-19', 'author': 'Boulware', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': 'key-10.4103/2277-9175.368527-12', 'unstructured': 'Guitti P, Parnaz P, Parichehr P, Fariba G. Prophylactic recommendation ' 'for healthcare workers in COVID-19 pandemic. Adv J Emerg Med 2020;4.'}, { 'key': 'key-10.4103/2277-9175.368527-13', 'doi-asserted-by': 'crossref', 'first-page': '177', 'DOI': '10.1080/10937404.2020.1752340', 'article-title': 'Challenges and cares to promote rational use of chloroquine and ' 'hydroxychloroquine in the management of coronavirus disease 2019 ' '(COVID-19) pandemic: A timely review', 'author': 'Pereira', 'year': '2020', 'journal-title': 'J Toxicol Environ Health B Crit Rev'}, { 'key': 'key-10.4103/2277-9175.368527-14', 'doi-asserted-by': 'crossref', 'first-page': '2493', 'DOI': '10.1001/jama.2020.8630', 'article-title': 'Association of treatment with hydroxychloroquine or azithromycin with ' 'in-hospital mortality in patients with COVID-19 in New York State', 'author': 'Rosenberg', 'year': '2020', 'journal-title': 'JAMA'}, { 'key': 'key-10.4103/2277-9175.368527-15', 'unstructured': 'Keshavan M. Hospital Workers Across the U.S. Present Sharply Different ' 'Pictures of their Preparedness for the Coronavirus. STAT. Available ' 'from: https://www.statnews.com/2020/03/. [Last accessed on 2020 Mar ' '14].'}, { 'key': 'key-10.4103/2277-9175.368527-16', 'doi-asserted-by': 'crossref', 'first-page': '865', 'DOI': '10.1016/j.jiph.2020.05.005', 'article-title': 'Hydroxychloroquine as antiviral prophylaxis for exposed caregivers to ' 'Covid-19: An urgent appraisal is needed', 'author': 'Tahiri', 'year': '2020', 'journal-title': 'J Infect Public Health'}, { 'key': 'key-10.4103/2277-9175.368527-17', 'unstructured': 'World Health Organization. Diagnostic Detection of 2019-nCoV by ' 'Real-Time RT-PCR. Available from: ' 'https://www.who.int/docs/default-source/coronaviruse/protocol-v2-1.pdf?sfvrsn=a9ef618c_2. ' '[Last accessed 2020 Dec 10].'}, { 'key': 'key-10.4103/2277-9175.368527-18', 'doi-asserted-by': 'crossref', 'first-page': 'e0242763', 'DOI': '10.1371/journal.pone.0242763', 'article-title': 'A multicenter, randomized, open-label, controlled trial to evaluate the ' 'efficacy and tolerability of hydroxychloroquine and a retrospective ' 'study in adult patients with mild to moderate coronavirus disease 2019 ' '(COVID-19)', 'author': 'Cheng', 'year': '2020', 'journal-title': 'PLoS One'}, { 'key': 'key-10.4103/2277-9175.368527-19', 'doi-asserted-by': 'crossref', 'first-page': '304', 'DOI': '10.1016/j.bj.2021.02.006', 'article-title': 'Artificial neural network and logistic regression modelling to ' 'characterize COVID-19 infected patients in local areas of Iran', 'author': 'Mohammadi', 'year': '2021', 'journal-title': 'Biomed J', 'ISSN': 'http://id.crossref.org/issn/2319-4170', 'issn-type': 'print'}, { 'key': 'key-10.4103/2277-9175.368527-20', 'doi-asserted-by': 'crossref', 'first-page': 'e2', 'DOI': '10.1016/S2665-9913(20)30390-8', 'article-title': 'Hydroxychloroquine in the prevention of COVID-19 mortality', 'author': 'Jorge', 'year': '2021', 'journal-title': 'Lancet Rheumatol'}, { 'key': 'key-10.4103/2277-9175.368527-21', 'doi-asserted-by': 'crossref', 'first-page': '195', 'DOI': '10.1001/jamainternmed.2020.6319', 'article-title': 'Efficacy and safety of hydroxychloroquine vs.placebo for pre-exposure ' 'SARS-CoV-2 prophylaxis among health care workers: A randomized clinical ' 'trial', 'author': 'Abella', 'year': '2021', 'journal-title': 'JAMA Intern Med'}, { 'key': 'key-10.4103/2277-9175.368527-22', 'doi-asserted-by': 'crossref', 'unstructured': 'Rajasingham R, Bangdiwala AS, Nicol MR, Skipper CP, Pastick KA, Axelrod ' 'ML, et al. Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 ' 'in healthcare workers: A randomized trial. medRxiv 2020; ' '2020.09.18.20197327.', 'DOI': '10.1101/2020.09.18.20197327'}, { 'key': 'key-10.4103/2277-9175.368527-23', 'doi-asserted-by': 'crossref', 'first-page': '497', 'DOI': '10.1016/S0140-6736(20)30183-5', 'article-title': 'Clinical features of patients infected with 2019 novel coronavirus in ' 'Wuhan, China', 'author': 'Huang', 'year': '2020', 'journal-title': 'Lancet'}, { 'key': 'key-10.4103/2277-9175.368527-24', 'doi-asserted-by': 'crossref', 'first-page': '1377', 'DOI': '10.1016/S0161-6420(02)01168-5', 'article-title': 'Recommendations on screening for chloroquine and hydroxychloroquine ' 'retinopathy: A report by the American Academy of Ophthalmology', 'author': 'Marmor', 'year': '2002', 'journal-title': 'Ophthalmology'}, { 'key': 'key-10.4103/2277-9175.368527-25', 'doi-asserted-by': 'crossref', 'first-page': '1786', 'DOI': '10.1016/j.drudis.2020.06.030', 'article-title': 'Repositioning chloroquine as ideal antiviral prophylactic against ' 'COVID-19-time is now', 'author': 'Chang', 'year': '2020', 'journal-title': 'Drug Discov Today'}], 'container-title': 'Advanced Biomedical Research', 'original-title': [], 'language': 'en', 'deposited': { 'date-parts': [[2023, 10, 27]], 'date-time': '2023-10-27T06:18:06Z', 'timestamp': 1698387486000}, 'score': 1, 'resource': {'primary': {'URL': 'https://journals.lww.com/10.4103/abr.abr_104_21'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023]]}, 'references-count': 25, 'journal-issue': {'issue': '1', 'published-print': {'date-parts': [[2023]]}}, 'alternative-id': ['368527'], 'URL': 'http://dx.doi.org/10.4103/abr.abr_104_21', 'relation': {}, 'ISSN': ['2277-9175'], 'subject': ['General Biochemistry, Genetics and Molecular Biology'], 'container-title-short': 'Adv Biomed Res', 'published': {'date-parts': [[2023]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit